Price of Pill that Will Likely Cure 90% of Hep C Patients | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Sovaldi™ (sofosbuvir) and Hepatitis C

Back to News Homepage
Next

Hep C Drug Pipeline: New Additions and Three Combos to Watch for in 2014

Price of Pill that Will Likely Cure 90% of Hep C Patients

The Editors at Hepatitis Central
January 2, 2014

Print this page

Learn about estimated costs for the drug sofosbuvir (brand name Sovaldi) that will help treat patients with Hepatitis C. Gregg Alton, a vice president at Gilead, comments that, “Gilead will help U.S. patients pay for sofosbuvir if they can’t afford it…or the company will help them look for drug coverage.”
The drug sofosbuvir (brand name Sovaldi) will cost $1,000 per pill. Pin it on Pinterest

$1,000 Pill For Hepatitis C Spurs Debate Over Drug Prices

Richard Knox December 30, 2013

Federal regulators this month opened a new era in the treatment of a deadly liver virus that infects three to five times more people than HIV. Now the question is: Who will get access to the new drug for hepatitis C, and when?

The drug sofosbuvir (brand name Sovaldi) will cost $1,000 per pill. A typical course of treatment will last 12 weeks and run $84,000, plus the cost of necessary companion drugs. Some patients may need treatment for twice as long.

Continue reading this entire article:
http://www.wbur.org/npr/256885858/-1-000-pill-for-hepatitis-c-spurs-debate-over-drug-prices

205 Comments
Share
Share
Previous

Sovaldi™ (sofosbuvir) and Hepatitis C

Back to News Homepage
Next

Hep C Drug Pipeline: New Additions and Three Combos to Watch for in 2014

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.